Description
The company offers two unique blood tests that utilize epigenetics to provide insights into coronary heart disease. The first test, Epi+Gen CHD, assesses the risk of a heart attack within the next three years by evaluating five single nucleotide polymorphisms and three DNA methylation markers in genomic DNA extracted from human peripheral whole blood. The second test, PrecisionCHD, specifically detects the presence of coronary heart disease. Both tests come with Actionable Clinical Intelligence, providing personalized reports on specific drivers of coronary heart disease, and HeartRisk, an Employer CVD Risk Intelligence platform that delivers a dashboard of population health cardiovascular disease statistics and aggregated employee CHD risk insights to assist in resource allocation for benefits.
Additional Details
Contact Details
Gallery
No images found!
Video
No url found!
There are no reviews yet.